Microcap MedTech Moving on U.S. Clinical Milestone

Sponsored:

Friday, March 27, 2026

Advancements in diabetes technology continue to accelerate as companies race to improve patient outcomes and quality of life. Continuous glucose monitoring (CGM) has become one of the fastest-growing segments in healthcare, but limitations around wearable devices, sensor longevity, and accuracy still leave room for innovation. The next frontier may lie in implantable solutions designed to deliver more precise, real-time data without the burden of external hardware.

Shares of Glucotrack, Inc. (NASDAQ: GCTK) are climbing sharply Friday morning after the company announced it is preparing to file an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration to support a planned U.S. clinical trial for its continuous blood glucose monitoring (CBGM) technology.

Glucotrack, a medical technology company focused on diabetes care, highlighted a series of 2025 milestones that have positioned it to advance into the next phase of development. The company’s CBGM system is designed as a long-term, fully implantable device that measures glucose directly from blood rather than interstitial fluid, aiming to eliminate the lag time commonly associated with traditional CGM systems.

A key step forward came with the completion of its first-in-human clinical trial conducted in Brazil. The five-day study evaluated the insertion, use, and removal of the device and met all primary and secondary endpoints. Results showed strong performance, including a Mean Absolute Relative Difference (MARD) of 7.7%, a 99% data capture rate, and no serious device-related adverse events, supporting both accuracy and safety.

The company has also expanded its clinical development program internationally. A follow-up feasibility study in Australia provided additional insights into system performance and helped refine both product design and clinical protocols ahead of future trials.

With those studies completed, Glucotrack has moved into U.S. clinical readiness. The company has secured a clinical trial site, engaged a clinical research organization, and completed design enhancements to improve functionality. It is currently in discussions with the FDA and expects to submit its IDE application in the second quarter of 2026, with the goal of initiating U.S. trials in the second half of the year, pending regulatory approval.

Beyond clinical progress, the company has strengthened its intellectual property position, receiving three U.S. patents covering key elements of its CBGM platform, including sensor chemistry, intravascular lead design, and low-power electronics. These patents support the long-term development of a device designed for up to three years of sensor life.

As Glucotrack advances toward U.S. clinical trials, investors appear to be responding to the potential of a differentiated approach in one of healthcare’s most dynamic and rapidly expanding markets. Shares of GCTK are up 33.5% to $1.46 in early trading Friday.

Sponsored: